Novartis Licenses Spark’s Retinal Gene Therapy Outside US in $170 Million Deal

January 26, 2018: By Jon Swedien

Voretigene neparvovec

Novartis will develop and commercialize Spark Therapeutics’ gene therapy, voretigene neparvovec, outside the US under a licensing deal potentially worth more than $170 million, Spark announced Jan. 24.

Philadelphia-based Spark will continue to commercialize the gene therapy in the US under the brand name Luxturna.

Novartis, of Basel, Switzerland, will pay Spark $105 million in cash up front, and Spark is eligible to receive up to an additional $65 million in cash milestone payments and a royalty on net sales outside the US, Spark said.

The additional payments will be based on near-term European regulatory approval and initial sales outside the US in certain markets, the companies said.

Spark will retain regulatory responsibility for obtaining European Medicines Agency approval for the gene therapy. Spark also entered into a separate agreement to manufacture and supply investigational voretigene neparvovec to Novartis, the companies said.

On Dec. 19, the US FDA approved Luxturna for the treatment of retinal dystrophies caused by mutations in the RPE65 gene. Those dystrophies include a form of Leber congenital amaurosis (LCA2), a rare form of retinitis pigmentosa (RP 20), and severe early childhood onset retinal dystrophy (SECORD). LCA2 is the most common of them.

Luxturna is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease, and the first adeno-associated virus (AAV) vector gene therapy approved in the US, according to Spark.

Dan Faga, Spark’s chief business officer, said the company intends to use the proceeds to continue to develop its pipeline of investigational gene therapies.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023